Back to Search
Start Over
Sirolimus-based therapy for kidney transplantation from expanded criteria donors.
- Source :
-
Transplantation [Transplantation] 2009 Apr 27; Vol. 87 (8 Suppl), pp. S11-3. - Publication Year :
- 2009
-
Abstract
- The new class of immunosuppressants--inhibitors of the mammalian target of rapamycin--has no nephrotoxicity and the capacity to inhibit vascular smooth cell proliferation. These characteristics may afford considerable clinical advantages in the transplantation of kidneys from expanded criteria donors (ECD). Six clinical experiences of the use of sirolimus (SRL) in ECD kidneys recipients have been reported in the literature. Although the results varied somewhat, probably due to differences in the types of deceased donor and in the immunosuppressive regimens used, it seems that a calcineurin inhibitor free, SRL-based protocol can assure a good immunosuppressive effect with less nephrotoxicity and a low incidence of cytomegalovirus infection. For recipients of ECD kidneys at low immunological risk, we would recommend a regimen based on antithymocyte globulin induction and SRL, mycophenolate mofetil, and steroids for maintenance. For strongly responding recipients, we recommend SRL combined with a reduced, 76% to 87% dose of calcineurin inhibitor.
- Subjects :
- Aged
Cadaver
Clinical Trials as Topic
Cytomegalovirus Infections prevention & control
Dose-Response Relationship, Drug
Humans
Medical History Taking
Postoperative Complications prevention & control
Postoperative Complications virology
Tissue Donors supply & distribution
Immunosuppressive Agents therapeutic use
Kidney Transplantation immunology
Patient Selection
Sirolimus therapeutic use
Tissue Donors statistics & numerical data
Subjects
Details
- Language :
- English
- ISSN :
- 1534-6080
- Volume :
- 87
- Issue :
- 8 Suppl
- Database :
- MEDLINE
- Journal :
- Transplantation
- Publication Type :
- Academic Journal
- Accession number :
- 19384180
- Full Text :
- https://doi.org/10.1097/TP.0b013e3181a058a1